1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies (2012)

Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies (2012)

  1. Calliope
    Psychiatr Clin North Am. 2012 Jun;35(2):357-74

    Ross S

    ABSTRACT
    Converging lines of evidence from pharmacologic, electrophysiologic, and behavioral research in animals strongly suggest that activation of cortical 5-hydroxytryptamine-2A receptors is the most critical step in initiating a cascade of biological events that accounts for serotonergic hallucinogen (SH) psychoactive properties.
    Psilocybin produces hyperfrontality with divergent prefrontal–subcortical activation in such a way as to increase cognitive and affective processing in the context of reduced gating and reduced focus on external stimulus processing.
    In contrast to all other drugs of abuse, SHs are not considered to be capable of producing sufficient reinforcing effects to cause dependence (addiction) syndromes.
    Given that SHs increase extracellular glutamate levels and activity in the prefrontal–limbic circuitry, it is possible that a normalization in functional connectivity in this network through a glutamate-dependent neuroplastic adaptation could produce an anti-addictive effect.